Why this ASX 200 blue chip stock could outperform CBA

Analysts think this blue chip is a better buy than CBA.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Strong first quarter growth in life sales and solid capitalisation make this ASX 200 blue chip an attractive investment option.
  • Potential regulatory changes could positively impact its financial outlook by reducing annuity liabilities and required capital.
  • Analysts forecast a 15.5% potential upside and a 19% total return, supported by favourable regulatory benefits and growth opportunities.

Commonwealth Bank of Australia (ASX: CBA) shares are a popular option for blue chip investors.

But given how expensive the big four bank's shares are following strong gains in recent years, the upside from here could be very limited.

Instead, investors might get better returns from the ASX 200 blue chip stock in this article.

Two brokers analysing stocks.

Image source: Getty Images

Which ASX 200 blue chip stock?

The stock we are going to look at today is annuities company Challenger Ltd (ASX: CGF).

Its shares may be close to a 52-week high, but the team at Bell Potter doesn't believe it is too late to invest. Especially given the release of a strong first quarter update. It said:

The quarterly updates, cover life new business sales, FUM flows and capital, adequacy. Life sales were up 4% year-on-year, helped by lifetime annuities and institutional fixed term annuities. Funds management FUM was weaker, down 3% for the quarter, with $2.3bn of positive market moves offset by $4.9bn in outflows. Challenger Life is strongly capitalised with a PCA ratio of 1.58 times.

Outside this, Bell Potter highlights that potential changes to rules from APRA could be a big positive for Challenger in the near term.

We discuss the illiquidity premium, noting the restrictiveness of the current rules, and consider some of the proposals being considered by APRA. We expect the new standard will allow a higher discount rate and will be more representative of the assets held – including longer dated corporate bonds and a wider range of issuers. The benefit should lead to a reduction in CGF's annuity liabilities (c$16bn at FY25) and could lead to a reduction to the $2.8bn of required capital, particularly asset charges (c$2bn) and stress scenarios (c$0.5bn).

Potential double-digit returns

According to the note, the broker has retained its buy rating on the ASX 200 blue chip stock with an improved price target of $10.25 (from $9.50).

Based on its current share price of $8.87, this implies potential upside of 15.5% over the next 12 months.

In addition, the broker is forecasting a fully franked dividend yield of 3.5%. This boosts the total potential return to 19%.

Commenting on its recommendation, Bell Potter said:

The medium term buy case is supported by both the freeing of capital from the APRA proposals and growth opportunities as Retiring Australians are offered advice and products to achieve an optimal retirement income. A small increase in the take up of annuities, with more favourable capital rules could dramatically increase the long-term growth of CGF. We expect positive news flow before the year-end. Despite a slightly mixed Q1, we increase our Target Price to $10.25/sh and maintain our BUY recommendation.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Challenger. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A man looking at his laptop and thinking.
Blue Chip Shares

3 top blue-chip ASX 200 shares that look dirt cheap right now

A buying opportunity could have opened up for patient investors.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Blue Chip Shares

2 fantastic ASX 200 shares to buy and hold for the next five years

Let's see why these shares could be quality picks for patient investors.

Read more »

A man in a suit looks serious while discussing business dealings with a couple as they sit around a computer at a desk in a bank home lending scenario.
Blue Chip Shares

2 ASX shares that could benefit from rising interest rates and oil prices

These two shares may be well-placed in the current environment.

Read more »

A person holds strong behind their umbrella as they weather the oncoming storm.
Blue Chip Shares

2 great ASX 200 blue-chip shares I'd buy right now

This looks like a good time to invest, in my view.

Read more »

An elephant standing on a chair looking down at a mouse
Blue Chip Shares

How are Australia's biggest blue-chip stocks performing in 2026?

Which has been the best to own this year?

Read more »

A family sitting on a couch watching Netflix
Blue Chip Shares

The ideal Australian stocks to buy and hold forever

Here are three ASX shares I would consider holding long term.

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Blue Chip Shares

Where to invest $5,000 in Australian shares for the rest of 2026

I think spreading investments across sectors can improve long-term outcomes.

Read more »

Two smiling work colleagues discuss an investment at their office.
Blue Chip Shares

Where I'd put $10,000 in Australian stocks right now

These two beaten down ASX stocks could look attractive for long-term investors.

Read more »